Target Name: MIR128-1
NCBI ID: G406915
Review Report on MIR128-1 Target / Biomarker Content of Review Report on MIR128-1 Target / Biomarker
MIR128-1
Other Name(s): hsa-mir-128-1 | MIR128A | hsa-miR-128-1-5p | MicroRNA 128-1 | mir-128-1 | microRNA 128-1 | MIRN128-1 | hsa-miR-128-3p | MIRN128A

MIR128-1: A Potential Drug Target and Biomarker for Melanoma

Melanoma is a deadly form of skin cancer that is characterized by the rapid growth of skin cells that can invade nearby tissues and organs. It is a leading cause of skin cancer death worldwide, with over 90% of all skin cancer deaths caused by melanoma. Despite advances in treatment, the survival rate for melanoma remains low, with a five-year survival rate of only around 40%.

The discovery of MIR128-1, a gene that has been identified as a potential drug target and biomarker for melanoma, has the potential to revolutionize the treatment of this disease. MIR128-1 is a non-coding RNA molecule that has been shown to be highly expressed in melanoma tissues and cell lines. It has been shown to play a role in the development and progression of melanoma, and has also been associated with the development of other types of cancer.

Initial Preclinical Studies

In order to understand the potential drug targets and biomarkers for melanoma, it is important to conduct preclinical studies to investigate the effects of MIR128-1 on melanoma growth and progression. This was done by a team of researchers led by Dr. Xinran Li, a Professor of Dermatology at the University of California, San Francisco (UCSF), who used a variety of techniques, including RNA interference, to knock down the expression of MIR128-1 in melanoma cells.

The results of these studies showed that MIR128-1 was highly expressed in melanoma tissues and cell lines, and that it was involved in the development and progression of melanoma. The researchers also found that overexpressing MIR128-1 in melanoma cells led to the growth of tumors, and that this was associated with the development of metastatic disease.

In addition to these findings, the researchers also observed that MIR128-1 was downregulated in the primary melanoma tissues, and that this was associated with the poor prognosis of these tumors. This suggests that MIR128-1 may be a useful biomarker for melanoma, and that it may also be a potential drug target.

Potential Drug Target

The potential drug target for MIR128-1 is the production of melanin, which is a pigment that gives skin its color. Melanin is produced by melanocytes, which are the cells responsible for the production of the pigment melanin. The production of melanin is regulated by several genes, including MIR128-1.

Research has shown that MIR128-1 plays a role in the production of melanin in melanocytes. By inhibiting the activity of MIR128-1, researchers have found that they can reduce the production of melanin, which can lead to the death of melanocytes and the progression of melanoma.

This suggests that MIR128-1 may be a potential drug target for melanoma. If MIR128-1 is indeed a drug target, then targeting this molecule may be an effective way to treat melanoma.

Potential Biomarker

In addition to its potential as a drug target, MIR128-1 may also be a useful biomarker for melanoma. The researchers who initially identified MIR128-1 have shown that MIR128-1 is highly expressed in melanoma tissues and cell lines, and that it is involved in the development and progression of this disease.

These findings suggest that MIR128-1 may be a useful biomarker for

Protein Name: MicroRNA 128-1

The "MIR128-1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MIR128-1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

MIR128-2 | MIR1280 | MIR1281 | MIR1282 | MIR1283-1 | MIR1283-2 | MIR1284 | MIR1285-1 | MIR1285-2 | MIR1286 | MIR1287 | MIR1288 | MIR1289-1 | MIR1289-2 | MIR129-1 | MIR129-2 | MIR1290 | MIR1291 | MIR1292 | MIR1293 | MIR1294 | MIR1295A | MIR1295B | MIR1296 | MIR1297 | MIR1298 | MIR1299 | MIR1301 | MIR1302-1 | MIR1302-10 | MIR1302-11 | MIR1302-2 | MIR1302-3 | MIR1302-4 | MIR1302-5 | MIR1302-6 | MIR1302-7 | MIR1302-8 | MIR1302-9 | MIR1303 | MIR1304 | MIR1305 | MIR1306 | MIR1307 | MIR130A | MIR130B | MIR132 | MIR1321 | MIR1322 | MIR1323 | MIR1324 | MIR133A1 | MIR133A1HG | MIR133A2 | MIR133B | MIR134 | MIR1343 | MIR135A1 | MIR135A2 | MIR135B | MIR136 | MIR137 | MIR137HG | MIR138-1 | MIR138-2 | MIR139 | MIR140 | MIR141 | MIR142 | MIR143 | MIR144 | MIR145 | MIR1468 | MIR1469 | MIR146A | MIR146B | MIR1470 | MIR1471 | MIR147A | MIR147B | MIR148A | MIR148B | MIR149 | MIR150 | MIR151A | MIR151B | MIR152 | MIR153-1 | MIR153-2 | MIR1537 | MIR1538 | MIR1539 | MIR154 | MIR155 | MIR155HG | MIR1587 | MIR15A | MIR15B | MIR16-1 | MIR16-2